for people ages 18-80 (full criteria)
at San Francisco, California and other locations
study started
estimated completion



The primary objective for this trial is to determine the effect of GB002 on improving pulmonary hemodynamics in subjects with World Health Organization (WHO) Group 1 PAH who are Functional Class (FC) II and III. The secondary objective for this trial is to determine the effect of GB002 on improving exercise capacity in this population.

Official Title

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Clinical Study to Evaluate the Efficacy and Safety of Oral Inhalation of GB002 for the Treatment of WHO Group 1 Pulmonary Arterial Hypertension (PAH)


Pulmonary Artery Hypertension Hypertension Generic Dry Powder Inhaler


You can join if…

Open to people ages 18-80

  1. A current diagnosis of symptomatic PAH classified by one of the following:
  2. Idiopathic PAH (IPAH) or heritable pulmonary arterial hypertension (HPAH).
  3. PAH associated with connective tissue diseases.
  4. PAH associated with anorexigen or methamphetamine use.
  5. Congenital heart disease with simple systemic to pulmonary shunt at least 1 year after surgical repair.
  6. 6MWD ≥ 150 meters and ≤ 550 meters at screening.
  7. WHO FC II or III symptomatology.
  8. Treatment with standard of care PAH background therapies.
  9. Documentation of cardiac catheterization within the screening period that is consistent with the diagnosis of PAH and meeting all the following criteria, to be confirmed by a central hemodynamic core laboratory:
  10. Mean pulmonary arterial pressure (mPAP) ≥ 25 mmHg (at rest);
  11. Pulmonary capillary wedge pressure ≤ 15 mmHg, or mean left atrial pressure (mLAP) or left ventricular-end diastolic pressure (LVEDP) ≤ 15 mmHg in the absence of left atrial obstruction;
  12. PVR ≥ 400 dyne•s/cm5.
  13. Pulmonary function tests (PFTs) and diffusing capacity of the lungs for carbon monoxide (DLCO) at screening with the following criteria met:
  14. Forced expiratory volume in 1 second (FEV1) ≥60% (predicted);
  15. DLCO ≥40% predicted except for subject with PAH associated with systemic sclerosis (SSc-APAH) where DLCO ≥30% is required.

You CAN'T join if...

  1. Evidence of chronic thromboembolic disease or acute pulmonary embolism as assessed by ventilation-perfusion (V/Q) scan, computed tomography (CT)-angiogram, or pulmonary angiogram prior to screening.
  2. Uncontrolled systemic hypertension as evidenced by sitting systolic blood pressure > 160 mm Hg or sitting diastolic blood pressure > 100 mm Hg during screening visit after a period of rest.
  3. Systolic blood pressure < 90 mm Hg during screening and baseline visits.
  4. WHO Pulmonary Hypertension Group 2-5.
  5. Human immunodeficiency virus (HIV)-associated PAH.
  6. History of left-sided heart disease and/or clinically significant cardiac disease.
  7. Untreated obstructive sleep apnea.
  8. History of atrial septostomy within 180 days prior to screening.
  9. Pulmonary venous occlusive disease (PVOD).
  10. . Moderate to severe hepatic impairment classified as Child-Pugh Class B or C at screening.
  11. . History of malignancy within 5 years prior to screening.
  12. . History of a potentially life-threatening cardiac arrhythmia with an ongoing risk.
  13. . Severe acute or chronic medical or laboratory abnormality that may increase the risk associated with study participation or IP administration (eg; history intracranial hemorrhage).
  14. . Chronic renal insufficiency as defined by an estimated glomerular filtration rate (eGFR) ≤ 30 mL/min via Chronic Kidney Disease Epidemiology Collaboration (CKD-epi) at screening or requires dialytic therapy or hemofiltration.
  15. . Hemoglobin (Hgb) concentration < 8.5 g/dL at screening.
  16. . Evidence of active HIV, Hepatitis B or Hepatitis C, or tuberculosis (TB) infections.
  17. . Inhaled prostanoids; these drugs must be withdrawn prior to or at screening.
  18. . Use of anticoagulants (ie, coumadin or NOAC) at randomization.
  19. . Requirement of intravenous (IV) inotropes (ie, levosimendan, dopamine, dobutamine, milrinone, norepinephrine) other than an IV prostanoid within 4 weeks of screening.
  20. . Prior participation in GB002 studies and/or prior treatment with GB002.
  21. . Currently participating in or has participated in a study of an investigational agent or has used an investigational device for the treatment of PAH within 4 weeks prior to screening.
  22. . Current use of inhaled tobacco.
  23. . A positive test for drugs of abuse (amphetamines, methamphetamines, cocaine, phencyclidine [PCP]).

NOTE: Additional inclusion/exclusion criteria may apply, per protocol.


  • The University of California San Francisco accepting new patients
    San Francisco California 94143 United States
  • The Lundquist Institute of Biomedical Innovation at Harbor-UCLA Medical Center accepting new patients
    Torrance California 90502 United States


accepting new patients
Start Date
Completion Date
GB002, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.
Phase 2
Study Type
Last Updated